Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMR Crisis Experts See Hopeful Signs For 2020

But Worries Rise US Politics May Stop Needed Progress

Executive Summary

2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip. 

You may also be interested in...



UK Experimental AMR Payment Program “On Track”

Designers of the UK’s experimental antibiotic payment system aim to identify two drugs later this year which will then undergo a novel technology assessment in 2021.

Destiny Pharma Seeks Partner For Lead Asset XF-73

Antimicrobial specialist Destiny Pharma aims to enlist a pharma partner later this year to help advance and launch its lead asset for preventing post-surgical infections.

Antabio CEO Says M&A Is His ‘Exit Strategy’

Antibiotics specialist Antabio aims to get enough funding to advance its pipeline far enough to become a takeover target.     

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel